Table 4.
Univariate analysis of TILs and the hematologic parameters associated with DFS in each of the breast cancer subtypes
| Variable | Disease-free survival | |||||
|---|---|---|---|---|---|---|
| HR+ | HER2+ | Triple-negative | ||||
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| AMC (high vs. low) | 1.68 (0.52–5.45) | 0.390 | 0.87 (0.27–2.74) | 0.809 | 5.18 (1.08–24.94) | 0.040* |
| ANC (high vs. low) | 0.47 (0.15–1.43) | 0.181 | 0.47 (0.15–1.47) | 0.194 | 1.03 (0.28–3.85) | 0.961 |
| ALC (high vs. low) | 0.26 (0.08–0.83) | 0.024* | 0.56 (0.18–1.77) | 0.323 | 0.34 (0.07–1.63) | 0.177 |
| NLR (high vs. low) | 1.06 (0.36–3.17) | 0.911 | 0.82 (0.26–2.54) | 0.729 | 2.54 (0.63–10.15) | 0.188 |
| LMR (high vs. low) | 0.13 (0.03–0.59) | 0.008* | 1.14 (0.36–3.58) | 0.828 | 0.23 (0.05–1.11) | 0.067 |
| PLR (high vs. low) | 0.87 (0.29–2.59) | 0.801 | 1.08 (0.34–3.42) | 0.892 | 1.49 (0.40–5.56) | 0.551 |
| CD8 (high vs. low) | 0.91 (0.30–2.71) | 0.860 | 0.65 (0.19–2.19) | 0.483 | 2.75 (0.69–10.99) | 0.153 |
| FOXP3 (high vs. low) | 0.78 (0.26–2.34) | 0.664 | 0.78 (0.25–2.43) | 0.664 | 1.41 (0.38–5.27) | 0.608 |
AMC absolute monocyte count, ALC absolute lymphocyte count, ANC absolute neutrophil count, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, FOXP3 forkhead box protein 3, HER2+ hormone receptor positive or negative/ HER2-positive, HR+ hormone receptor positive/HER2-negative
*p < 0.05